Clinical outcome of decitabine combined with CAG regimen in the treatment of patients with relapsed refractory acute myeloid leukemia
10.3760/cma.j.issn.1009-9921.2014.03.007
- VernacularTitle:地西他滨联合CAG方案治疗复发难治性急性髓系白血病的临床观察
- Author:
Hongxia YU
;
Juan HE
- Publication Type:Journal Article
- Keywords:
Leukemia,myeloid,acute;
Decitabine;
Recurrence;
Refractory
- From:
Journal of Leukemia & Lymphoma
2014;23(3):152-155
- CountryChina
- Language:Chinese
-
Abstract:
Objective To discuss the efficacy and safety of decitabine plus aclacinomycin/cytarabine/ G-CSF (CAG) regimen in the treatment of patients with relapsed refractory acute myeloid leukemia (AML).Methods 17 cases with relapsed refractory AML were collected.They were given decitabine (25 mg/d,d1-5) plus CAG regimen (aclacinomycin 20 mg/d,d3-6; cytarabine 10 mg/m2,d3-9; G-CSF 400 μg/d,d0-9).Results After one course treatment by decitabine plus CAG regimen,10 patients (58.8 ％) achieved complete response (CR),1 patient (5.9 ％) achieved partial response (PR) and 6 patients (35.3 ％) displayed no response (NR),the overall response rate was 64.7 ％ (11/17).For karyotyping of chromosomal abnormalities,only 1 case (100 ％) in CR showed normal karyotype.8 cases (66.7 ％) in CR,1 case (8.3 ％) in PR showed medium karyotype.1 case (25.0 ％) in CR showed bad karyotype.Statistical analysis revealed that there were significant differences among different groups (P ＜ 0.05).Follow-up to January 31,2013,15 patients survived,2 patients died early.The median overall survival was 67 d (14-307 d),and the median relapse-free survival was 47 d (14-152 d).Conclusions The combined regimen of decitabine and CAG in the treatment of patients with relapsed refractory AML has a high response rate,little non-hematologic side effects and good tolerance.
